Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Plos One|February 26, 2013
A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteriaCharles F Gilks, A Sarah Walker, Paula Munderi, et al.
Plos One|March 15, 2014
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trialCissy Kityo, Diana M Gibb, Charles F Gilks, et al.
The Lancet. HIV|November 29, 2015
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort studyAnna Turkova, Elizabeth Chappell, Ali Judd, et al.
AIDS Research and Human Retroviruses|August 11, 2015
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East AfricaKatherine A Sutherland, Ruth L Goodall, Adele McCormick, et al.
BMC Infectious Diseases|February 23, 2017
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial dataDavid I Dolling, Ruth L Goodall, Michael Chirara, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 6, 2010
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoringFred Lyagoba, David T Dunn, Deenan Pillay, et al.
The Journal of Infectious Diseases|November 27, 2009
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus AbacavirNicaise Ndembi, Nicasie Ndembi, Ruth L Goodall, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Lancet (London, England)|November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
Pageof 3